The Cupertino company plans to open healthcare clinics that will rely heavily on its technology. Also, Gilead Sciences partners with Sangamo Therapeutics on gene-editing.

Thanks to LegalZoom for supporting Motley Fool.  Get special savings by going to legalzoom.com use code Fool at checkout.

With revenue trending downward for several years running, General Mills is focused on stabilizing the top line, and management hopes that buying into a whole new industry will do the trick. Blue Buffalo Pet Products is the leader in natural pet foods, but will its double-digit top line growth be enough to move the needle?

With revenue trending downward for several years running, General Mills is focused on stabilizing the top line, and management hopes that buying into a whole new industry will do the trick. Blue Buffalo Pet Products is the leader in natural pet foods, but will its double-digit top line growth be enough to move the needle?

Financials takes a look into the latest letter The Oracle of Omaha wrote for Berkshire Hathaway’s shareholders.

Financials takes a look into the latest letter The Oracle of Omaha wrote for Berkshire Hathaway’s shareholders.

February was a busy month for tech earnings -- today we backtrack to look at results and news for Snap and Twitter.

February was a busy month for tech earnings -- today we backtrack to look at results and news for Snap and Twitter.

We grapple with last quarter’s results and discuss the company’s worsening free cash flow position, delivery expectations, and margin goals.

We grapple with last quarter’s results and discuss the company’s worsening free cash flow position, delivery expectations, and margin goals.

Despite significant risks, Berkshire Hathaway’s become Teva Pharmaceutical’s 9th biggest investor. Also, what gives with Rite Aid’s convoluted merger plans?